NCT01427946 2014-11-13
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
Infinity Pharmaceuticals, Inc.
Phase 1/2 Completed
Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc.